<DOC>
	<DOCNO>NCT01576549</DOCNO>
	<brief_summary>This study investigate LY2127399 work participant rheumatoid arthritis ( RA ) adequately respond methotrexate . Participants receive LY2127399 via injection ( ) skin 4 week interval 52 week . Key study procedure include biopsy line inflamed joint blood test measure RA activity .</brief_summary>
	<brief_title>A Study LY2127399 Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Diagnosis adult onset RA disease accord revised 1987 American Rheumatism Association ( ARA ) criterion currently document history positive rheumatoid factor ( RF ) and/or anticyclic citrullinated peptide antibody ( antiCCP Ab ) moderately severely active RA despite ongoing methotrexate ( MTX ) therapy Have active RA define presence least 8/68 tender least 8/66 swollen joint , determine tender joint count swell joint count assessment form Have screen Creactive protein ( CRP ) measurement great 1.2 time upper limit normal erythrocyte sedimentation rate ( ESR ) great 28 mm/hr Have clinically inflame joint suitable synovial biopsy procedure Have use unstable dose nonsteroidal antiinflammatory drug ( NSAIDs ) within 6 week prior baseline Have use oral corticosteroid average daily dose &gt; 10 mg/day prednisone equivalent within 6 week prior baseline Have receive parenteral corticosteroid injection within 6 week baseline Have use diseasemodifying antirheumatic drug ( DMARDs ) MTX , hydroxychloroquine and/or sulfasalazine 8 week prior baseline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>